[{"data":1,"prerenderedAt":177},["ShallowReactive",2],{"drug-nirmatrelvir-ritonavir":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":22,"regimens":37,"contraindications":68,"warnings":85,"renal":93,"monitoring":94,"interactions":95,"review":96,"examples":99,"atc":105,"iran":107,"links":114,"populations":130,"usApproval":172},"nirmatrelvir-ritonavir",1,{"fa":7,"en":8},"نیرماترلویر + ریتوناویر","Nirmatrelvir + ritonavir","anti-infectives",{"fa":11,"en":12},"مهارکننده پروتئاز SARS-CoV-2","SARS-CoV-2 protease inhibitor",[14],{"name":15,"market":16},"Paxlovid","US",[18,19,20,21],"paxlovid","پکسلووید","پاکسلووید","نیرماترلویر",[23],{"id":24,"form":25,"route":26,"label":27,"concentration":28,"markets":32,"refs":33},"tab-150","tablet","oral","Nirmatrelvir 150 mg tablet (co-packaged with ritonavir 100 mg)",{"amount":29,"unit":30,"perUnit":25,"scored":31},150,"mg",false,[16],[34],{"source":35,"section":36},"fda-paxlovid","3",[38],{"id":39,"disease":40,"label":41,"population":44,"type":48,"unit":30,"dose":49,"refs":52,"durationDays":55,"notes":57},"covid","covid-19",{"fa":42,"en":43},"کووید-۱۹ خفیف تا متوسط در بزرگسال پرخطر — ۳۰۰ mg نیرماترلویر + ۱۰۰ mg ریتوناویر دو بار در روز، ۵ روز","Mild–moderate COVID-19 in high-risk adults — nirmatrelvir 300 mg + ritonavir 100 mg twice daily, 5 days",{"minAge":45},{"value":46,"unit":47},18,"year","fixed",{"perDose":50,"dosesPerDay":51},300,2,[53],{"source":35,"section":54},"2.2",{"min":56,"max":56},5,[58],{"text":59,"refs":62},{"fa":60,"en":61},"هر نوبت: ۲ قرص نیرماترلویر + ۱ قرص ریتوناویر با هم. eGFR ۳۰ تا ۶۰: ۱۵۰ mg + ۱۰۰ mg دو بار در روز. eGFR زیر ۳۰: روز اول ۳۰۰ + ۱۰۰ یک بار، روز ۲ تا ۵ ۱۵۰ + ۱۰۰ یک بار. نارسایی شدید کبد توصیه نمی‌شود.","Each dose: 2 nirmatrelvir tablets + 1 ritonavir tablet together. eGFR 30–60: 150 mg + 100 mg twice daily. eGFR \u003C30: day 1 300 + 100 once, days 2–5 150 + 100 once daily. Not recommended in severe hepatic impairment.",[63,64,66],{"source":35,"section":54},{"source":35,"section":65},"2.3, Table 1",{"source":35,"section":67},"2.4",[69,78],{"id":70,"severity":71,"text":72,"refs":75},"hyper","block",{"fa":73,"en":74},"سابقه حساسیت مهم (TEN، استیونس-جانسون) به نیرماترلویر یا ریتوناویر.","History of clinically significant hypersensitivity (TEN, Stevens-Johnson) to nirmatrelvir or ritonavir.",[76],{"source":35,"section":77},"4",{"id":79,"severity":71,"text":80,"refs":83},"cyp",{"fa":81,"en":82},"داروهایی که عمدتاً با CYP3A متابولیزه می‌شوند و افزایش سطح آن‌ها خطرناک است، و القاکننده‌های قوی CYP3A — فهرست کامل در بخش ۴ برچسب.","Drugs highly dependent on CYP3A where raised levels are dangerous, and strong CYP3A inducers — full list in label section 4.",[84],{"source":35,"section":77},[86],{"text":87,"refs":90},{"fa":88,"en":89},"هشدار جعبه‌ای: تداخلات دارویی مهم (ریتوناویر مهارکننده قوی CYP3A)؛ پیش از تجویز همه داروهای بیمار بررسی شود.","Boxed warning: significant drug interactions (ritonavir is a strong CYP3A inhibitor); review all medicines before prescribing.",[91],{"source":35,"section":92},"Boxed Warning",[],[],[],{"status":97,"reviewer":98,"date":98},"unverified",null,[100],{"regimen":39,"formulation":24,"input":101,"expect":104},{"ageYears":102,"weightKg":103},60,70,{"perDose":50,"tabletsPerDoseRounded":51},[106],"J05AE30",{"status":108,"refs":109},"not-found",[110],{"source":111,"section":112,"url":113},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Nirmatrelvir%20%2B%20ritonavir",[115,119,123,127],{"kind":116,"url":117,"label":118},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=217188","NDA217188",{"kind":120,"url":121,"label":122},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=8a99d6d6-fd9e-45bb-b1bf-48c7f761232a","FDA Paxlovid",{"kind":124,"url":125,"label":126},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa622005.html","Nirmatrelvir and Ritonavir",{"kind":128,"url":129,"label":106},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=J05AE30",{"pregnancy":131,"lactation":140,"pediatric":148,"geriatric":156,"reproductive":164},{"level":132,"text":133,"quote":136,"refs":137},"caution",{"fa":134,"en":135},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Available data on the use of nirmatrelvir during pregnancy are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.",[138],{"source":35,"section":139},"8.1",{"level":132,"text":141,"quote":144,"refs":145},{"fa":142,"en":143},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary Nirmatrelvir and ritonavir are present in human breast milk in small amounts (less than 2%).",[146],{"source":35,"section":147},"8.2",{"level":132,"text":149,"quote":152,"refs":153},{"fa":150,"en":151},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The optimal dose of PAXLOVID has not been established in pediatric patients.",[154],{"source":35,"section":155},"8.4",{"level":132,"text":157,"quote":160,"refs":161},{"fa":158,"en":159},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Clinical studies of PAXLOVID include subjects 65 years of age and older and their data contributes to the overall assessment of safety and efficacy [see Adverse Reactions (6.1) and Clinical Studies (14.1) ] .",[162],{"source":35,"section":163},"8.5",{"level":132,"text":165,"quote":168,"refs":169},{"fa":166,"en":167},"برچسب نکته‌ای درباره بارداری، پیشگیری یا باروری زنان و مردان دارد.","Label has advice on pregnancy testing, contraception or fertility for females and males.","Contraception Use of ritonavir may reduce the efficacy of combined hormonal contraceptives.",[170],{"source":35,"section":171},"8.3",{"kind":173,"refs":174,"id":118},"NDA",[175],{"source":35,"section":176},"SPL approval \u002F marketing category",1792108432027]